Abstract:AIMS:Pathological cardiac hypertrophy induced by activation of the renin-angiotensin-aldosterone system (RAAS) is one of the leading causes of heart failure. However, in current clinical practice, the strategy for targeting the RAAS is not sufficient to reverse hypertrophy. Here, we investigated the effect of prostaglandin E1 (PGE1) on angiotensin II (AngII)-induced cardiac hypertrophy and potential molecular mechanisms underlying the effect.METHODS AND RESULTS:Adult male C57 mice were continuously infused with AngII or saline and treated daily with PGE1 or vehicle for two weeks. Neonatal rat cardiomyocytes were cultured to detect AngII-induced hypertrophic responses. We found that PGE1 ameliorated AngII-induced cardiac hypertrophy both in vivo and in vitro. The RNA sequencing (RNA-seq) and expression pattern analysis results suggest that Netrin-1 (Ntn1) is the specific target gene of PGE1. The protective effect of PGE1 was eliminated after knockdown of Ntn1. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that the PGE1-mediated signaling pathway changes are associated with the mitogen-activated protein kinase (MAPK) pathway. PGE1 suppressed AngII-induced activation of the MAPK signaling pathway, and such an effect was attenuated by Ntn1 knockdown. Blockade of MAPK signaling rescued the phenotype of cardiomyocytes caused by Ntn1 knockdown, indicating that MAPK signaling may act as the downstream effector of Ntn1. Furthermore, inhibition of the E-prostanoid (EP) 3 receptor, as opposed to the EP1, EP2, or EP4 receptor, in cardiomyocytes reversed the effect of PGE1, and activation of EP3 by sulprostone, a specific agonist, mimicked the effect of PGE1.CONCLUSION:In conclusion, PGE1 ameliorates AngII-induced cardiac hypertrophy through activation of the EP3 receptor and upregulation of Ntn1, which inhibits the downstream MAPK signaling pathway. Thus, targeting EP3, as well as the Ntn1-MAPK axis, may represent a novel approach for treating pathological cardiac hypertrophy.

Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac Hypertrophy.

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E<sub>2</sub> receptor EP2 subtype

Prostaglandin E2 affects mitochondrial function in adult mouse cardiomyocytes and hearts

Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction

Prostaglandin E1 Attenuates AngII-induced Cardiac Hypertrophy Via EP3 Receptor Activation and Netrin-1upregulation

Prostaglandin E Receptors in Regulation of Blood Pressure

The Double Roles of the Prostaglandin E2 EP2 Receptor in Intracerebral Hemorrhage

Activation of E-Prostanoid 3 Receptor in Macrophages Facilitates Cardiac Healing after Myocardial Infarction

An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases

Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts

Targeted Disruption of the Prostaglandin E2 E-prostanoid 2 Receptor Exacerbates Vascular Neointimal Formation in Mice.

Abstract 9711: Cardioprotection by Endogenous Cardiac Myocyte P2x4; Receptors in Pressure Overload and Ischemic Heart Failure

PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2

The Latest Progress in E-Prostanoid (EP) Receptor Subtypes EP2 and EP4

The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension

Role of Prostaglandin E2 Receptor 4 in the Modulation of Apoptosis and Mitophagy During Ischemia/reperfusion Injury in the Kidney.

Prostaglandin E2 Induced Cardiac Hypertrophy Through EP2 Receptor‐dependent Activation of Β‐catenin in 5/6 Nephrectomy Rats

Calcium Signal Pathway is Involved in Prostaglandin E-2 Induced Cardiac Fibrosis in Cardiac Fibroblasts

EP4 Activation Ameliorates Liver Ischemia/reperfusion Injury Via ERK1/2‑GSK3β‑dependent MPTP Inhibition.

Cyclic AMP-dependent Modulation of Cardiac L-type Ca2+ and Transient Outward K+ Channel Activities by Epoxyeicosatrienoic Acids.